The list of controlled substances posted on the DHEC website is for informational purposes only. The posted list includes all substances scheduled in accordance with the provisions of SC Code Section 44-53-160, designated by the DHEC Board and transmitted to the General Assembly since the last SC Code update in 2012, as well as the list of scheduled substances currently in the SC Code for Schedules I-V. Please review the Board Orders posted on this page, as well as the Federal Register, for detailed information on the scheduling actions of controlled substances.
| Drug | Common Name | Schedule | Date of DHEC Schedule | Code Section |
|---|---|---|---|---|
| 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one | Methoxetamine | C-I | 06/29/2022 | 44-53-190 |
| [(3-hydroxy-3-methyl-5-pregnan-20-one) | Ganaxolone | C-V | 06/29/2022 | 44-53-270 |
| N,N-diethyl-2-(5-nitro-2-( 4-propoxybenzyl)-lH-benzimidazol-l-yl)ethan-1- amine | Protonitazene | C-I | 05/05/2022 | 44-53-160(C) |
| 2-( 4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-lH-benzimidazole | N-Pyrrolidino etonitazene | C-I | 05/05/2022 | 44-53-160(C) |
|
N,N-diethyl-2-(2-( 4-methoxybenzyl)-5-nitro-lH-benzimidazol-1-yl)ethan-l- amine |
Metonitazene |
C-I | 05/05/2022 | 44-53-160(C) |
| N,N-diethyl-2-(2-(4-methoxybenzyl)-lHbenzimidazol-1-yl)ethan-1-amine | Metodesnitazene | C-I | 05/05/2022 | 44-53-160(C) |
|
N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-lH-benzimidazol-1-yl)ethan-1- amine |
Flunitazene | C-I | 05/05/2022 | 44-53-160(C) |
|
2-(2-( 4-ethoxybenzyl)-lH-benzimidazol-1-yl)-N,N-diethylethan-1-amine |
Etodesnitazene | C-I | 05/05/2022 | 44-53-160(C) |
| 2-(2-(4-butoxybenzyl)-5-nitro-IH-benzimidazol-l-yl)-N,Ndiethylethan-l- amine |
Butonitazene |
C-I | 05/05/2022 | 44-53-160(C) |
| 4,4′-Dimethylaminorex; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4- methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 4,4′-DMAR | C-I | 09/09/2021 | 44-53-160(C) |
|
1-(4- methoxyphenyl)-N-methylpropan-2- amine (paramethoxymethamphetamine |
para-Methoxymethamphetamine (PMMA) |
C-I |
07/15/2021 |
44-53-160(C) |
|
methyl 2-(1- (4-fluorobutyl)-1H-indazole-3- carboxamido)-3,3-dimethylbutanoate |
4F–MDMB–BUTINACA |
C-I |
07/15/2021 |
44-53-160(C) |
| 3-[[[(1S)-1-carboxy-2-hydroxyethyl]- amino]carbonyl]-1-[[[[(2R)-2-[(1R)-2-methoxy-2-oxo-1-phenylethyl]-1- piperidinyl]carbonyl]oxy]methyl]pyridinium chloride | Serdexmethylphenidate | C-IV | 05/13/2021 | 44-53-160(C) |
| Ethyl (1-phenethylpiperidin-4- yl)(phenyl)carbamate (fentanyl carbamate) | Fentanyl Carbamate | C-1 | 05/13/2021 | 44-53-160(C) |
| N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide (ortho-fluoroacryl fentanyl) | Ortho-fluoroacryl Fentanyl | C-1 | 05/13/2021 | 44-53-160(C) |
| N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (ortho-fluoroisobutyryl fentanyl) | Ortho-fluoro Isobutyryl Fentanyl | C-1 | 05/13/2021 | 44-53-160(C) |
| N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2-carboxamide (para-fluoro furanyl fentanyl) | Para-fluoro Furanyl Fentanyl | C-1 | 05/13/2021 | 44-53-160(C) |
|
N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide |
2′-Fluoro Ortho-fluorofentanyl | C-1 | 05/13/2021 | 44-53-160(C) |
| N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4′-methyl acetyl fentanyl) | 4′- methyl acetyl fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-phenyl-N-(1-(2- phenylpropyl)piperidin-4- yl)propionamide (b-methyl fentanyl) | b-methyl fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl) | orthofluorobutyryl fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-(2-methylphenyl)-N-(1- phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl) | ortho-methyl acetylfentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| 2-methoxy-N-(2-methylphenyl)-N- (1-phenethylpiperidin-4-yl)acetamide (ortho-methylmethoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl) | Ortho-methyl Methoxyacetyl Fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4- methylfentanyl) | Paramethyl Fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl) | Phenyl Fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl) | Thiofuranyl Fentanyl | C-I | 05/13/2021 | 44-53-160(C) |
| Oliceridine N-[(3- methoxythiophen-2-yl)methyl] ({2- [(9R)-9-(pyridin-2-yl)-6- oxaspiro [4.5]decan-9-yl]ethyl})amine fumarate | Oliceridine | C-II | 11/12/2020 | 44-53-210 |
| Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide) | Crotonyl Fentanyl | C-I | 10/08/2020 | 44-53-190(B) |
| Remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid, 8-bromo-1-methyl-6-(2-pyridinyl)-(4S)- methyl ester, benzenesulfonate (1:1) or methyl 3-[(4S)-8-bromo-1-methyl-6- pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4yl]propanoate benzenesulfonic acid) | Remimazolam | C-IV | 10/08/2020 | 44-53-250(A) |
| N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: isotonitazene; N,N-diethyl-2-[[4- (1-methylethoxy)phenyl]methyl]- 5-nitro-1H-benzimidazole-1- ethanamine) | Isotonitazene | C-I | 9/10/2020 | 44-53-190(B) |
| N-phenyl-N- (piperidin-4-yl)propionamide (norfentanyl) | Norfentanyl | C-II | 5/7/2020 | 45-53-210 |
| Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester) | Cenobamate | C-V | 4/9/2020 | 44-53-270 |
| Lemborexant (1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5- fluoropyridin-2-yl)cyclopropane-1-carboxamide | Lemborexant | C-IV | 4/9/2020 | 44-53-250 |
| Lasmiditan (2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide) and its salts, isomers, and salts of isomers. | Lasmiditan | C-V | 2/13/2020 | 44-53-270 |
| N-Ethylhexedrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other name: 2-(ethylamino)-1-phenylhexan-1-one) | N-Ethylhexedrone | C-I | 8/8/2019 | 44-53-190(F) |
| alpha-Pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: α-PHP; alpha-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) | α-PHP | C-I | 8/8/2019 | 44-53-190(F) |
| 4-Methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4–MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) | 4-MEAP | C-I | 8/8/2019 | 44-53-190(F) |
| 4′-Methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: MPHP; 4′-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one) | MPHP | C-I | 8/8/2019 | 44-53-190(F) |
| alpha-Pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) | PV8 | C-I | 8/8/2019 | 44-53-190(F) |
| 4′-Chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-chloro-α-PVP; 4′-chloro-alpha-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) | 4-Chloro-α-PVP | C-I | 8/8/2019 | 44-53-190(F) |
| Solriamfetol (2-amino-3-phenylpropyl car-bamate; benzenepropanol, beta-amino-, carbamate (ester)) | Solriamfetol | C-IV | 7/11/2019 | 44-53-250(b) |
| Brexanolone | Brexanolone | C-IV | 7/11/2019 | 44-53-250(a) |
| ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers | 5F-EDMB-PINACA | C-I | 5/9/2019 | 44-53-190(D) |
| methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers | 5F-MDMB-PICA | C-I | 5/9/2019 | 44-53-190(D) |
| N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers | FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL) | C-I | 5/9/2019 | 44-53-190(D) |
| 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers | 5F-CUMYL-PINACA; SGT-25 | C-I | 5/9/2019 | 44-53-190(D) |
| (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, its optical, positional, and geometric isomers, salts and salts of isomers | FUB-144 | C-I | 5/9/2019 | 44-53-190(D) |
| N-Ethylpentylone, its optical, positional, and geometric isomers, salts and salts of isomers | ephylone, N-1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone | C-I | 9/27/2018 | 44-53-160(C) |
| Naphthalen-1-yl 1-(5-fluoropentyl)-1 H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers | NM2201; CBL2201 | C-I | 7/12/2018 | 44-53-160(C) |
| N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers | 5F-AB-PINACA | C-I | 7/12/2018 | 44-53-160(C) |
| 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers | 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78 | C-I | 7/12/2018 | 44-53-160(C) |
| methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers | MMB-CHMICA, AMB-CHMICA | C-I | 7/12/2018 | 44-53-160(C) |
| 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers | 5F-CUMYL-P7AICA | C-I | 7/12/2018 | 44-53-160(C) |
| Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. (a) Fentanyl-related substance means any substance that is structurally related to fentanyl by one or more of the following modifications: 1. Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle; 2. Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups; 3. Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups; 4. Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or 5. Replacement of the N-propionyl group by another acyl group. | C-I | 2/8/2018 | 44-53-190(B) | |
| N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Valeryl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Para-Fluorobutyryl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Para-Methoxybutyryl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Para-Chloroisobutyryl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Isobutyryl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Cyclopentyl Fentanyl | C-I | 2/8/2018 | 44-53-190(B) |
| N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers |
Ocfentanil | C-I | 2/8/2018 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide(cyclopropyl fentanyl), its isomers, esters, ethers, salts and salts of isomers, esters and ethers | Cyclopropyl Fentanyl | C-I | 1/30/2018 | 44-53-190(B) |
| MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) | MT-45 | C-I | 1/4/2018 | 44-53-190(B) |
| methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, its isomers, esters, ethers, salts and salts of isomers, esters and ethers | FUB-AMB, MMB-FUBINACA, AMB-FUBINACA | C-I | 11/9/2017 | 44-53-190(D) |
| N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers | Ortho-Fluorofentanyl, 2-Fluorofentanyl | C-I | 11/9/2017 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers | Tetrahydrofuranyl Fentanyl | C-I | 11/9/2017 | 44-53-190(B) |
| 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers | Methoxyacetyl Fentanyl | C-I | 11/9/2017 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers | Acryl Fentanyl | C-I | 8/10/2017 | 44-53-190(B) |
| 4-Fluoroisobutyryl Fentanyl | N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl fentanyl or parafluoroisobutyryl fentanyl) | C-I | 5/11/2017 | 44-53-190(B) |
| Dronabinol [(-)-delta-9-trans tetrahydrocannabinol (delta-9-THC)] in an oral solution | Syndros | C-II | 4/5/2017 | 44-53-210 (Other) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide | Furanyl Fentanyl | C-I | 12/8/2016 | 44-53-190(B) |
| 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide | U-47700, (9547), PINK | C-I | 11/10/2016 | 44-53-190(B) |
| (4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl]piperidine) | Thiafentanil | C-II | 9/8/2016 | 44-53-210(c) |
| (4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl]piperidine) | Thiafentanyl | C-II | 9/8/2016 | 44-53-210(c) |
| ((2S)-2-[4R)-2-oxo-4-propypyrrolidin-1-yl] butanamide)Brivaracetam | BRV, UCB-34714, Briviact | C-V | 6/9/2016 | 44-53-270(c) |
| 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide | AH-7921 | C-I | 5/12/2016 | 44-53-190(B) |
| N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide | Butyryl Fentanyl | C-I | 5/12/2016 | 44-53-190(B) |
| N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpriopionamide | Beta-Hydroxythiofentanyl | C-I | 5/12/2016 | 44-53-190(B) |
| Updated Definition of Substiuted Cathinones to include underlined portion: (4) Substituted Cathinones, Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (a) by substitution in the phenyl ring to any extent with alkyl, alkenyl, alkoxy, alkylendioxy, haloalkyl, or halide subsituents, whether or not further substituted in the phenyl ring by one or more univalent substituents; (b) by substitution at the 3-position with an alkyl substituent; (c) by substitution at the nitrogen atom with alkyl or dialkyl groups, benzyl, or methoxybenzyl groups; or (d) by inclusion of the nitrogen atom in a cyclic structure. | Including but not limited to: Methylone, Mephedrone, MDPV, Butylone, Methedrone, 4-MEC, Flephedrone, Pentylone, Pentedrone, Buphedrone, alpha-PVP, 4-MePPP, 4-FMC, 3-FMC, alpha-PBP, naphyrone | C-I | 3/10/2016 | 44-53-190(F) |
| 5-[[[(2s)-2-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]2-methoxybenzoic acid | Eluxadoline | C-IV | 12/10/2015 | 44-53-250(e) |
| N-(1- phenethylpiperidin-4-yl)-N-phenylacetamide | Acetyl Fentanyl | C-I | 6/11/2015 | 44-53-190(B) |
| Syntehtic Cannabinoids: Indazole-3-carboxamides. Any compound containing an Indazole-3-carboxamide structure with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, halobenzyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent. Including, but not limited, to AKB-48, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, ADB-PINACA. | AKB-48, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, ADB-PINACA, AB-CHMINACA, THJ-2201, 5-Fluoro-AMB | C-I | 12/11/2014 | 44-53-190(D) |
| 13-beta-ethyl-17beta-hydroxygon-4-en-3-one | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 17-alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 17-alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 17-alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 17-alpha-methyl-4-hydroxynandrolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 17-alpha-methyl-delta1-dihydrotestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 19-nor-4,9(10)-androstadienedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 19-nor-4-androstenediol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 19-nor-4-androstenedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 19-nor-5-androstenediol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 19-nor-5-androstenedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 1-androstenediol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 1-androstenedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 3-alpha,17beta-dihydroxy-5alpha-androstane | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 3-beta,17beta-dihydroxy-5alpha-androstane | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 4-androstenediol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 4-androstenedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 4-dihydrotestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 4-hydroxy-19-nortestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 4-hydroxytestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 5-androstenediol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 5-androstenedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| androstanedione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| bolasterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| boldenone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| boldione | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| calusterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| delta1-dihydrotestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| desoxymethyltestosterone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| drostanolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| formebolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| furazabol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| mestanolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| methandriol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| methyldienolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| methyltrienolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| mibolerone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| norbolethone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| norclostebol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| normethandrolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| prostanozol | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| stenbolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| testolactone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| tetrahydrogestrinone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| trenbolone | Anabolic Steroids | 12/11/2014 | 44-53-1510 | |
| 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine | 2C-E | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine | 2C-I | C-I | 12/11/2014 | 44-53-190(D) |
| 4-Bromo-2,5-dimethoxyphenethylamine | 2C-B | C-I | 12/11/2014 | 44-53-190(D) |
| 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine | PEPAP | C-I | 12/11/2014 | 44-53-190(B) |
| 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine | TCPy | C-I | 12/11/2014 | 44-53-190(D) |
| 1-Methyl-4-phenyl-4-propionoxypiperidine | MPPP | C-I | 12/11/2014 | 44-53-190(B) |
| 2-(2,5-Dimethoxy-4-(n)-prophylphenyl) ethanamine | 2C-P | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine | 2C-D | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine | 2C-N | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(2,5-Dimethoxyphenyl) ethanamine | 2C-H | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine | 2C-C | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(4-ethylthio-2,5-dimethoxyphenyl) ethanamine | 2C-T-2 | C-I | 12/11/2014 | 44-53-190(D) |
| 2-(4-ethylthio-2,5-dimethoxyphenyl) ethanamine | 2C-T-4 | C-I | 12/11/2014 | 44-53-190(D) |
| 2,5-Dimethoxy-4-(n)propylthiophenethylamine | 2C-T-7 | C-I | 12/11/2014 | 44-53-190(D) |
| 2,5-Dimethoxy-4-ethylamphetamine | DOE, DOET, Hecate | C-I | 12/11/2014 | 44-53-190(D) |
| 3,4-Methylenedioxy-N-ethylamphetamine | MDEA | C-I | 12/11/2014 | 44-53-190(D) |
| 3-Methoxy-4,5-methylenedioxyamphetamine | MMDA | C-I | 12/11/2014 | 44-53-190(D) |
| 3-Methylfentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| 3-Methylthiofentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| 4-Methylaminorex (cis isomer) | C-I | 12/11/2014 | 44-53-190(F) | |
| 5 Methoxy-N,N,Dimethyltryptamine | 5-MeO-DMT | C-I | 12/11/2014 | 44-53-190(D) |
| 5-Iodo-2-aminoindane | 5-IAI | C-I | 12/11/2014 | 44-53-190(D) |
| 5-Methoxy-N,N-diisopropyltryptamine | 5-MeO-DIPT | C-I | 12/11/2014 | 44-53-190(D) |
| Acetyl-alpha-methylfentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| Alpha-ethyltryptamine | alpha-ET | C-I | 12/11/2014 | 44-53-190(D) |
| Alpha-methylthiofentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| Alpha-methyltryptamine | AMT | C-I | 12/11/2014 | 44-53-190(D) |
| Aminorex | C-I | 12/11/2014 | 44-53-190(F) | |
| Beta-hydroxy-3-methylfentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| Beta-hydroxyfentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| Cyclohexamine | Ethylamine analog of phencyclidine, PCE | C-I | 12/11/2014 | 44-53-190(D) |
| N,N-Dimethylamphetamine | Metrotonin | C-I | 12/11/2014 | 44-53-190(F) |
| N-Benzylpiperazine | BZP | C-I | 12/11/2014 | 44-53-190(F) |
| Para-Fluorofentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| Rolicyclidine | Pyrrolidine analog of phencyclidine, PHP, PCPy | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: Indole -3-carboxamides. Any compound containing an Indole-3-carboxamide structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent. Including, but not limited, to STS-135. | STS-135 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: Indazole-3-carboxamides. Any compound containing an Indazole-3-carboxamide structure with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent. Including, but not limited, to AKB-48, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, ADB-PINACA. | AKB-48, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, ADB-PINACA, AB-CHMINACA, THJ-2201, 5-Fluoro-AMB | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: N-cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecanamide | CB-52 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide | CB-25 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: N-cyclopropyl-8-[3-(1,1-dimethylheptyl)-5-hydroxyphenoxy]-octanamide | CB-86 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: (6aR,9R,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydrobenzo [c]chromene-1,9-diol | HU-243, Canbisol | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: [(6S,6aR, 9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate | Levantradol, CP 50,556-1 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: 1-napthalenyl[4-(pentylox)-1-napthalenyl]-methanone | CB-13, CRA-13 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione | HU-331 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1] hept-2-ene-2-methanol | HU-308 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannabinoids: Quinolinyl-Indole Carboxylates. Any compound containing a quinolinyl-indole-3-carboxylate structure with substitution of the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl) ethyl group, whether or not further substituted in the indole ring or quinolinyl structure to any extent. Including but not limited to PB-22, 5-F-PB-22. | PB-22; 5-F-PB-22; BB-22 | C-I | 12/11/2014 | 44-53-190(D) |
| Synthetic Cannaninoid: Indole - 3-ylcycloalkyl ketones. Any compound containing an Indole-3-ylcycloalkyl ketone structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (1-(N-methyl-2-piperidinyl)methyl, (tetrahydro-2H-pyran-4-yl)methyl or (morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent or whether or not substituted at the cycloalkyl ring to any extent. Including, but not limited to, XLR-11, UR-144, A-834735, A-796260, AB-001, AB-005 | XLR-11, UR-144, A-834735, A-796260, AB-001, AB-005, 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-144, AB-034 | C-I | 12/11/2014 | 44-53-190(D) |
| Tenocyclidine | 1-[1-(2-Thienyl)cyclohexyl]piperidine, TCP | C-I | 12/11/2014 | 44-53-190(D) |
| Thiofentanyl | C-I | 12/11/2014 | 44-53-190(B) | |
| 4-Anilino-N-phenethyl-4-piperidine | ANPP | C-II | 12/11/2014 | 44-53-210(c) |
| Alfentanil | C-II | 12/11/2014 | 44-53-210(c) | |
| Dihydroetorphine | C-II | 12/11/2014 | 44-53-210(c) | |
| Diprenorphine | C-II | 12/11/2014 | 44-53-210(c) | |
| Levo-alphacetylmethadol | LAAM | C-II | 12/11/2014 | 44-53-210(c) |
| Lisdexamfetamine | C-II | 12/11/2014 | 44-53-210(d) | |
| Nabilone | C-II | 12/11/2014 | 44-53-210(h) | |
| Oripavine | C-II | 12/11/2014 | 44-53-210(c) | |
| Oxycodone | C-II | 12/11/2014 | 44-53-210(c) | |
| Remifentanil | C-II | 12/11/2014 | 44-53-210(c) | |
| Tapentadol | C-II | 12/11/2014 | 44-53-210(c) | |
| Thebaine | C-II | 12/11/2014 | 44-53-210(c) | |
| Buprenorphine | C-III | 12/11/2014 | 44-53-230(e) | |
| Dronabinol in sesame oil and encapsulated in a soft gelatin capsule | marinol - synthetic delta 9 tetrahydrocannabinol (THC) | C-III | 12/11/2014 | 44-53-230(e) |
| Embutramide | C-III | 12/11/2014 | 44-53-230(c) | |
| Ketamine | C-III | 12/11/2014 | 44-53-230(c) | |
| Sulfonmethane | C-III | 12/11/2014 | 44-53-230(c) | |
| Tiletamine & Zolazepam Combination Product | C-III | 12/11/2014 | 44-53-230(c) | |
| Cathine | C-IV | 12/11/2014 | 44-53-250(b) | |
| Dichloralphenazone | C-IV | 12/11/2014 | 44-53-250(a) | |
| Etizolam | C-IV | 12/11/2014 | 44-53-250(a) | |
| Fencamfamin | C-IV | 12/11/2014 | 44-53-250(b) | |
| Fenproporex | C-IV | 12/11/2014 | 44-53-250(b) | |
| Fospropofol | C-IV | 12/11/2014 | 44-53-250(a) | |
| Mefenorex | C-IV | 12/11/2014 | 44-53-250(b) | |
| Midazolam | C-IV | 12/11/2014 | 44-53-250(a) | |
| Modafinil | C-IV | 12/11/2014 | 44-53-250(b) | |
| Phenazepam | C-IV | 12/11/2014 | 44-53-250(a) | |
| Pyrazolam | C-IV | 12/11/2014 | 44-53-250(a) | |
| Quazepam | C-IV | 12/11/2014 | 44-53-250(a) | |
| Sibutramine | C-IV | 12/11/2014 | 44-53-250(b) | |
| Zaleplon | C-IV | 12/11/2014 | 44-53-250(a) | |
| Zolpidem | C-IV | 12/11/2014 | 44-53-250(a) | |
| Zopiclone | C-IV | 12/11/2014 | 44-53-250(a) | |
| Lacosamide | C-V | 12/11/2014 | 44-53-270(c) | |
| Pregabalin | C-V | 12/11/2014 | 44-53-270(c) | |
| Pyrovalerone | C-V | 12/11/2014 | 44-53-270(d) | |
| [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl}{5=methyl-2-(2H-123-triazol-2-yl)phenyl]methanone | Suvorexant | C-IV | 9/25/2014 | 44-53-250(a) |
| Dihydrocodeine - Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. | C-II | 9/11/2014 | 44-53-230(e) | |
| Dihydrocodeine - Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a four-fold or greater quantity of an isoquinoline alkaloid of opium. | C-II | 9/11/2014 | 44-53-230(e) | |
| Dihydrocodeine - Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. | C-II | 9/11/2014 | 44-53-230(e) | |
| Hydrocodone Combination Products | Lortab | C-II | 9/11/2014 | 44-53-210(c) |
| 2-[(dimethylamino)methyl]-1-(3-Methoxyphenyl)cyclohexanol | Tramadol | C-IV | 7/10/2014 | 44-53-250(e) |
| Alfaxalone | Alfaxalone | C-IV | 3/13/2014 | 44-53-250(a) |
| Synthetic Cannabinoid: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide | ADB-PINACA | C-I | 2/27/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: N-(1-amino-3-methyl-1-oxobutan-2-yl-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide | AB-FUBINACA | C-I | 2/27/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3 carboxylate | 5-fluoro-PB-22; 5F-PB-22 | C-I | 2/27/2014 | 44-53-190(D) |
| Synthetic Cannabinoid: Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate | PB-22; QUPIC | C-I | 2/27/2014 | 44-53-190(D) |
| 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine | 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36 | C-I | 12/12/2013 | 44-53-190(D) |
| 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine | 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82 | C-I | 12/12/2013 | 44-53-190(D) |
| 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine | 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5 | C-I | 12/12/2013 | 44-53-190(D) |
| Lorcaserin | Lorcaserin | C-IV | 6/4/2013 | 44-53-250(c) |
| Synthetic Cannabinoid: 1-(5-fluoro-pentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone | 5-fluoro-UR-144; XLR-11; XLRl 1 | C-I | 5/9/2013 | 44-53-190(D) |
| Synthetic Cannabinoid: 1-pentyl-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl) methanone | UR-144 | C-I | 5/9/2013 | 44-53-190(D) |
| Synthetic Cannabinoid: N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide | APINACA, AKB48 | C-I | 5/9/2013 | 44-53-190(D) |
| Carisoprodol | Soma | C-IV | 2/9/2012 | 44-53-250(a) |
| Carisoprodol+Aspirin | SOMA Compound | C-IV | 2/9/2012 | 44-53-250(a) |
| 3,4-methylenedioxy-N-methylcathinone | Methylone | C-I | 10/24/2011 | 44-53-190(F) |
| 3,4-methylenedioxypyrovalerone | MDPV | C-I | 10/24/2011 | 44-53-190(F) |
| 4-methyl-N-methylcathinone | Mephedrone | C-I | 10/24/2011 | 44-53-190(F) |
| Synthetic Cannabinoid: 1-Butyl-3-(1-napthoyl)indole | JWH-073 | C-I | 10/24/2011 | 44-53-190(D) |
| Synthetic Cannabinoid: 1-Pentyl-3-(1-napthoyl)indole | JWH-018; AM678 | C-I | 10/24/2011 | 44-53-190(D) |
| Synthetic Cannabinoid: 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | CP-47,497 | C-I | 10/24/2011 | 44-53-190(D) |
| Synthetic Cannabinoid: 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | cannabicyclohexanol; CP-47,497 C8 homologue | C-I | 10/24/2011 | 44-53-190(D) |
| Synthetic Cannabinoid: 1-[2-(4-Morpholinyl)ethyl]-3-(1-napthoyl)indole | JWH-200 | C-I | 10/24/2011 | 44-53-190(D) |
| Ethylestrenol | Anabolic Steroids | 44-53-1510 | ||
| Fluoxymesterone | Anabolic Steroids | 44-53-1510 | ||
| Mesterolone | Anabolic Steroids | 44-53-1510 | ||
| Methandienone | Anabolic Steroids | 44-53-1510 | ||
| Methandrostenolone | Anabolic Steroids | 44-53-1510 | ||
| Methenolone | Anabolic Steroids | 44-53-1510 | ||
| Methyltestosterone | Anabolic Steroids | 44-53-1510 | ||
| Nandrolone | Anabolic Steroids | 44-53-1510 | ||
| Norethandrolone | Anabolic Steroids | 44-53-1510 | ||
| Oxandrolone | Anabolic Steroids | 44-53-1510 | ||
| Oxymesterone | Anabolic Steroids | 44-53-1510 | ||
| Oxymetholone | Anabolic Steroids | 44-53-1510 | ||
| Stanozolol | Anabolic Steroids | 44-53-1510 | ||
| Testosterone | Anabolic Steroids | 44-53-1510 | ||
| 2,5-dimethoxyamphetamine | C-I | 44-53-190(D) | ||
| 3,4,5-trimethoxy amphetamine | C-I | 44-53-190(D) | ||
| 3,4-methylenedioxy amphetamine | C-I | 44-53-190(D) | ||
| 3,4-methylenedioxymethamphetamine (MDMA) | C-I | 44-53-190(D) | ||
| 4-bromo-2,5-dimethoxyamphetamine | C-I | 44-53-190(D) | ||
| 4-Methoxyamphetamine | C-I | 44-53-190(D) | ||
| 4-methyl-2,5-dimethoxyamphetamine (STP) | C-I | 44-53-190(D) | ||
| 5-methoxy-3,4-methylenedioxy amphetamine | C-I | 44-53-190(D) | ||
| Acetorphine | C-I | 44-53-190(C) | ||
| Acetyldihydrocodeine | C-I | 44-53-190(C) | ||
| Acetylmethadol | C-I | 44-53-190(B) | ||
| Alfentanyl | C-I | 44-53-190(B) | ||
| Allylprodine | C-I | 44-53-190(B) | ||
| Alphacetylmethadol | C-I | 44-53-190(B) | ||
| Alphameprodine | C-I | 44-53-190(B) | ||
| Alphamethadol | C-I | 44-53-190(B) | ||
| Alphamethylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl-4-(N-pro-panilido) piperidine) | C-I | 44-53-190(B) | ||
| Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (a) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more univalent substituents; (b) by substitution at the 3-position with an alkyl substituent; (c) by substitution at the nitrogen atom with alkyl or dialkyl groups, benzyl or methoxybenzyl groups; or (d) by inclusion of the nitrogen atom in a cyclic structure | Including, but not limited to: Methylone, Mephedrone, 3,4-Methylenedioxypyrovalerone (MDPV), Butylone, Methedrone, 4-Methylethcathinone, Flephedrone, Pentylone, Pentedrone, Buphedrone | C-I | 44-53-190(F) | |
| Benzethidine | C-I | 44-53-190(B) | ||
| Benzylmorphine | C-I | 44-53-190(C) | ||
| Betacetylmethadol | C-I | 44-53-190(B) | ||
| Betameprodine | C-I | 44-53-190(B) | ||
| Betamethadol | C-I | 44-53-190(B) | ||
| Betaprodine | C-I | 44-53-190(B) | ||
| Bufotenine | C-I | 44-53-190(D) | ||
| Cathinone | C-I | 44-53-190(F) | ||
| Clonitazene | C-I | 44-53-190(B) | ||
| Codeine methylbromide | C-I | 44-53-190(C) | ||
| Codeine-N-Oxide | C-I | 44-53-190(C) | ||
| Cyprenorphine | C-I | 44-53-190(C) | ||
| Desomorphine | C-I | 44-53-190(C) | ||
| Dextromoramide | C-I | 44-53-190(B) | ||
| Diampromide | C-I | 44-53-190(B) | ||
| Diethylthiambutene | C-I | 44-53-190(B) | ||
| Diethyltryptamine (DET) | C-I | 44-53-190(D) | ||
| Difenoxin | C-I | 44-53-190(B) | ||
| Dihydromorphine | C-I | 44-53-190(C) | ||
| Dimenoxadol | C-I | 44-53-190(B) | ||
| Dimepheptanol | C-I | 44-53-190(B) | ||
| Dimethylthiambutene | C-I | 44-53-190(B) | ||
| Dimethyltryptamine (DMT) | C-I | 44-53-190(D) | ||
| Dioxaphetyl butyrate | C-I | 44-53-190(B) | ||
| Dipipanone | C-I | 44-53-190(B) | ||
| Drotebanol | C-I | 44-53-190(C) | ||
| Ethylmethylthiambutene | C-I | 44-53-190(B) | ||
| Etonitazene | C-I | 44-53-190(B) | ||
| Etorphine | C-I | 44-53-190(C) | ||
| Etoxeridine | C-I | 44-53-190(B) | ||
| Fenethylline | C-I | 44-53-190(F) | ||
| Furethidine | C-I | 44-53-190(B) | ||
| Gamma Hydroxybutyric Acid | C-I | 44-53-190(E) | ||
| Heroin | C-I | 44-53-190(C) | ||
| Hydromorphinol | C-I | 44-53-190(C) | ||
| Hydroxypethidine | C-I | 44-53-190(B) | ||
| Ibogaine | C-I | 44-53-190(D) | ||
| Ketobemidone | C-I | 44-53-190(B) | ||
| Levomoramide | C-I | 44-53-190(B) | ||
| Levophenacylmorphan | C-I | 44-53-190(B) | ||
| Lysergic acid diethylamide (LSD) | C-I | 44-53-190(D) | ||
| Marijuana | C-I | 44-53-190(D) | ||
| Mecloqualone | C-I | 44-53-190(E) | ||
| Mescaline | C-I | 44-53-190(D) | ||
| Methaqualone | C-I | 44-53-190(E) | ||
| Methyldesorphine | C-I | 44-53-190(C) | ||
| Methylhydromorphine | C-I | 44-53-190(C) | ||
| Morpheridine | C-I | 44-53-190(B) | ||
| Morphine methylbromide | C-I | 44-53-190(C) | ||
| Morphine methylsulfonate | C-I | 44-53-190(C) | ||
| Morphine-N-Oxide | C-I | 44-53-190(C) | ||
| Myrophine | C-I | 44-53-190(C) | ||
| N-ethyl-3-piperidyl benzilate | C-I | 44-53-190(D) | ||
| N-ethylamphetamine | C-I | 44-53-190(F) | ||
| Nicocodeine | C-I | 44-53-190(C) | ||
| Nicomorphine | C-I | 44-53-190(C) | ||
| N-methyl-3-piperidyl benzilate | C-I | 44-53-190(D) | ||
| Noracymethadol | C-I | 44-53-190(B) | ||
| Norlevorphanol | C-I | 44-53-190(B) | ||
| Normethadone | C-I | 44-53-190(B) | ||
| Normorphine | C-I | 44-53-190(C) | ||
| Norpipanone | C-I | 44-53-190(B) | ||
| Parahexyl | C-I | 44-53-190(D) | ||
| Peyote | C-I | 44-53-190(D) | ||
| Phenadoxone | C-I | 44-53-190(B) | ||
| Phenampromide | C-I | 44-53-190(B) | ||
| Phenomorphan | C-I | 44-53-190(B) | ||
| Phenoperidine | C-I | 44-53-190(B) | ||
| Pholcodine | C-I | 44-53-190(C) | ||
| Piritramide | C-I | 44-53-190(B) | ||
| Proheptazine | C-I | 44-53-190(B) | ||
| Properidine | C-I | 44-53-190(B) | ||
| Propiram | C-I | 44-53-190(B) | ||
| Psilocybin | C-I | 44-53-190(D) | ||
| Psilocyn | C-I | 44-53-190(D) | ||
| Racemoramide | C-I | 44-53-190(B) | ||
| Substituted Cathinones | C-I | 44-53-190(F) | ||
| Synthetic Cannabinoid 24 (d.) Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent | C-I | 44-53-190(D) | ||
| Synthetic Cannabinoid 24 (e.) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. | Including, but not limited to, SR-18, RCS-8, JWH-203, JWH-250, JWH-251, JWH-302 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24 (f.) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. | Including, but not limited to, CP 47,497 (and homologues), cannabicyclohexanol, CP-55, 940. | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24 (h.) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN 55,212-2) | WIN 55,212-2 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24 (i.) 9-(hydroxymethyl)-6,6-dimethy l-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370 (HU-210, HU-211) | HU-210, HU-211 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24 (j.) Adamantoylindoles. Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring system to any extent | Including but not limited to: AB-001, AB-002, AM1248 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24(g.) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. | Including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, AM-630, AM-1241, AM-2233 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24. (a.) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. | Including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398, AM-2201, WIN 55-212, AM-2201 (C1 analog), AM-1220 | C-I | 44-53-190(D) | |
| Synthetic cannabinoid 24. (b.) Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent | Including but not limited to: JWH-175, JWH-184 | C-I | 44-53-190(D) | |
| Synthetic Cannabinoid 24. (c.) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. | Including, but not limited to, JWH-307, JWH-370, JWH-176 | C-I | 44-53-190(D) | |
| Synthetic cannabinoids.--24. Any material, compound, mixture, or preparation that is not listed as a controlled substance in Schedule I through V, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, and salts of isomers and homologues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, and salts of isomers and homologues is possible within the specific chemical designation. | C-I | 44-53-190(D) | ||
| Tetrahydrocannabinol (THC) | C-I | 44-53-190(D) | ||
| Thebacon | C-I | 44-53-190(C) | ||
| Thiophene analog of phencyclidine | C-I | 44-53-190(D) | ||
| Tilidine | C-I | 44-53-190(B) | ||
| Trimeperidine | C-I | 44-53-190(B) | ||
| Alphaprodine | C-II | 44-53-210(c) | ||
| Amobarbital | C-II | 44-53-210(f) | ||
| Amphetamine, its salts, optical isomers, and salts of its optical isomers | C-II | 44-53-210(d) | ||
| Anileridine | C-II | 44-53-210(c) | ||
| Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium | C-II | 44-53-210(b) | ||
| Bezitramide | C-II | 44-53-210(c) | ||
| Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine | C-II | 44-53-210(b) | ||
| Dextropropoxyphene [alpha-(+" )-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane], in bulk form | C-II | 44-53-210(c) | ||
| Dihydrocodeine | C-II | 44-53-210(c) | ||
| Diphenoxylate | C-II | 44-53-210(c) | ||
| Fentanyl | C-II | 44-53-210(c) | ||
| Isomethadone | C-II | 44-53-210(c) | ||
| Levomethorphan | C-II | 44-53-210(c) | ||
| Levorphanol | C-II | 44-53-210(c) | ||
| Metazocine | C-II | 44-53-210(c) | ||
| Methadone | C-II | 44-53-210(c) | ||
| Methadone - Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane | C-II | 44-53-210(c) | ||
| Methamphetamine, its salts, and salts of isomers | C-II | 44-53-210(d) | ||
| Methylphenidate | C-II | 44-53-210(d) | ||
| Moramide - Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid | C-II | 44-53-210(c) | ||
| Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding Apomorphine, Nalbuphine, Naloxone, and Naltrexone, and their respective salts | C-II | 44-53-210(b) | ||
| Opium poppy and poppy straw | C-II | 44-53-210(b) | ||
| Pentazocine (to be administered by injection only) | C-II | 44-53-210(c) | ||
| Pentobarbital | C-II | 44-53-210(f) | ||
| Pethidine - Intermediate-A, 4-cyano-1-methyl-4-phenyl-piperidine | C-II | 44-53-210(c) | ||
| Pethidine - Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate | C-II | 44-53-210(c) | ||
| Pethidine - Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid | C-II | 44-53-210(c) | ||
| Pethidine (meperidine) | C-II | 44-53-210(c) | ||
| Phenazocine | C-II | 44-53-210(c) | ||
| Phencyclidine immediate precursors: (a) 1-phenylcyclohexylamine; (b) 1-piperidinocyclohexanecarbonitrile (PCC); (g) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance: (1) Immediate precursor to amphetamine and methamphetamine: (i) Phenylacetone, also known as phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone. | C-II | 44-53-210(f) | ||
| Phencyclidine | C-II | 44-53-210(f) | ||
| Phenmetrazine and its salts | C-II | 44-53-210(d) | ||
| Phenylacetone (Immediate precurser to amphetamine or methamphetamine) | phenyl-2-propanone, P2P, benzyl methyl ketone, methyl benzyl ketone | C-II | 44-53-210(g) | |
| Piminodine | C-II | 44-53-210(c) | ||
| Racemethorphan | C-II | 44-53-210(c) | ||
| Racemorphan | C-II | 44-53-210(c) | ||
| Secobarbital | C-II | 44-53-210(f) | ||
| Sufentanil | C-II | 44-53-210(c) | ||
| any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active ingredients which are not listed in any schedule | C-III | 44-53-230(c) | ||
| any substance which contains any quantity of a derivative or barbituric acid or any salt thereof; | C-III | 44-53-230(c) | ||
| any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the United States Food and Drug Administration for marketing only as a suppository; | C-III | 44-53-230(c) | ||
| Benzphetamine | C-III | 44-53-230(b) | ||
| Chlorhexadol | C-III | 44-53-230(c) | ||
| Chlorphentermine | C-III | 44-53-230(b) | ||
| Clortermine | C-III | 44-53-230(b) | ||
| Gamma Hydroxybutyric Acid, and its salts, isomers, and salts of isomers contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug and Cosmetic Act | C-III | 44-53-230(c) | ||
| Glutehimide | C-III | 44-53-230(c) | ||
| Lysergic Acid | C-III | 44-53-230(c) | ||
| Lysergic Acid Amide | C-III | 44-53-230(c) | ||
| Methyprylon | C-III | 44-53-230(c) | ||
| Nalorphene | C-III | 44-53-230(d) | ||
| Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium. | C-III | 44-53-230(e) | ||
| Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts | C-III | 44-53-230(e) | ||
| Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. | C-III | 44-53-230(e) | ||
| Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts. | C-III | 44-53-230(e) | ||
| Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. | C-III | 44-53-230(e) | ||
| Phendimetrazine | C-III | 44-53-230(b) | ||
| Sulfondiethylmethane | C-III | 44-53-230(c) | ||
| Sulfonethylmethane | C-III | 44-53-230(c) | ||
| Sulfonmethane | C-III | 44-53-230(c) | ||
| Fenfluramine | C-IV | 44-53-250(c) | ||
| Alprazolam | C-IV | 44-53-250(a) | ||
| Barbital | C-IV | 44-53-250(a) | ||
| Bromazepam | C-IV | 44-53-250(a) | ||
| Butorphanol | C-IV | 44-53-250(g) | ||
| Camazepam | C-IV | 44-53-250(a) | ||
| Chloral Betaine | C-IV | 44-53-250(a) | ||
| Chloral Hydrate | C-IV | 44-53-250(a) | ||
| Chlordiazepoxide | C-IV | 44-53-250(a) | ||
| Clobazam | C-IV | 44-53-250(a) | ||
| Clonazepam | C-IV | 44-53-250(a) | ||
| Clorazepate | C-IV | 44-53-250(a) | ||
| Clotiazepam | C-IV | 44-53-250(a) | ||
| Cloxazolam | C-IV | 44-53-250(a) | ||
| Delorazepam | C-IV | 44-53-250(a) | ||
| Diazepam | C-IV | 44-53-250(a) | ||
| Diethylpropion | C-IV | 44-53-250(b) | ||
| Dosage forms of Dextropropoxyphene [Alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane] | C-IV | 44-53-250(e) | ||
| Estazolam | C-IV | 44-53-250(a) | ||
| Ethchlorvynol | C-IV | 44-53-250(a) | ||
| Ethinamate | C-IV | 44-53-250(a) | ||
| Ethyl Loflazepate | C-IV | 44-53-250(a) | ||
| Fludiazepam | C-IV | 44-53-250(a) | ||
| Flunitrazepam | C-IV | 44-53-250(a) | ||
| Flurazepam | C-IV | 44-53-250(a) | ||
| Halazepam | C-IV | 44-53-250(a) | ||
| Haloxazolam | C-IV | 44-53-250(a) | ||
| Ketazolam | C-IV | 44-53-250(a) | ||
| Loprazolam | C-IV | 44-53-250(a) | ||
| Lorazepam | C-IV | 44-53-250(a) | ||
| Lormetazepam | C-IV | 44-53-250(a) | ||
| Mazindol | C-IV | 44-53-250(b) | ||
| Mebutamate | C-IV | 44-53-250(a) | ||
| Medazepam | C-IV | 44-53-250(a) | ||
| Meprobamate | C-IV | 44-53-250(a) | ||
| Methohexital | C-IV | 44-53-250(a) | ||
| Methylphenobarbital | C-IV | 44-53-250(a) | ||
| Nimetazepam | C-IV | 44-53-250(a) | ||
| Nitrazepam | C-IV | 44-53-250(a) | ||
| Nordiazepam | C-IV | 44-53-250(a) | ||
| Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. | C-IV | 44-53-250(e) | ||
| Oxazepam | C-IV | 44-53-250(a) | ||
| Oxazolam | C-IV | 44-53-250(a) | ||
| Paraldehyde | C-IV | 44-53-250(a) | ||
| Pemoline, including organometallic complexes and chelates thereof | C-IV | 44-53-250(b) | ||
| Pentazocine hydrochloride and acetaminophen, pentazocine hydrochloride and aspirin, and pentazocine and naloxone hydrochloride (all for oral administration only). | C-IV | 44-53-250(f) | ||
| Petrichloral | C-IV | 44-53-250(a) | ||
| Phenobarbital | C-IV | 44-53-250(a) | ||
| Phentermine | C-IV | 44-53-250(b) | ||
| Pinazepam | C-IV | 44-53-250(a) | ||
| Pipradol | C-IV | 44-53-250(b) | ||
| Prazepam | C-IV | 44-53-250(a) | ||
| SPA [(-)-1-Dimethylamino-1, 2-diphenylethane] | C-IV | 44-53-250(b) | ||
| Temazepam | C-IV | 44-53-250(a) | ||
| Tetrazepam | C-IV | 44-53-250(a) | ||
| Triazolam | C-IV | 44-53-250(a) | ||
| Not more than 200 milligrams of codeine per 100 milliliter or per 100 grams | C-V | 44-53-250(b) | ||
| Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams; | C-V | 44-53-250(b) | ||
| Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams; | C-V | 44-53-250(b) | ||
| Not more than 100 milligrams of opium per 100 milliliters or per 100 grams | C-V | 44-53-250(b) | ||
| Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; | C-V | 44-53-250(b) | ||
| Not more than one-half milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. | C-V | 44-53-250(b) |